Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population

European Journal of Human Genetics

Volumn 23, Issue 5, 2015, Pages 588-595

  Van Den Broek, Alexandra J ^a   De Ruiter, Karen ^a   Van 'T Veer, Laura J ^a   Tollenaar, Rob A E M ^b   Van Leeuwen, Flora E ^a   Verhoef, Senno ^a   Schmidt, Marjanka K ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER DIAGNOSIS; CANCER RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BREAST NEOPLASMS; CANCER STAGING; GENETIC SCREENING; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; MIDDLE AGED; MUTATION; NETHERLANDS; REPRODUCIBILITY; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NETHERLANDS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84928083355     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2014.161     Document Type: Article

References (42)

1. Antoniou A, Pharoah PD, Narod S et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
2. Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE 4. J Natl Cancer Inst 2013; 105: 812-822.
3. Brohet RM, Velthuizen ME, Hogervorst FB et al: Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations 1. J Med Genet 2014; 51: 98-107.
4. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
5. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-1333.
6. Liebens FP, Carly B, Pastijn A, Rozenberg S: Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007; 43: 238-257.
7. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A: Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 2007; 121: 225-231.
8. Domchek SM, Rebbeck TR: Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. LDI Issue Brief 2010; 16: 1-4.
9. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
10. Narod SA: BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7: 702-707.
11. Sandhu SK, Yap TA, de Bono JS: The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets 2011; 12: 2034-2044.
12. Sandhu SK, Yap TA, de Bono JS: Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010; 46: 9-20.
13. Rahman N, Stratton MR: The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95-121.
14. Thompson D, Easton D: The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9: 221-236.
15. Surbone A: Social and ethical implications of BRCA testing. Ann Oncol 2011; 22(Suppl 1): i60-i66.
16. Gadzicki D, Evans DG, Harris H et al: Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2: 53-69.
17. NABON. CBO (Dutch Institute for Healthcare Improvement) guideline for breast cancer; 2012. Available at: http://www.oncoline.nl/mammacarcinoom (last accessed on 26 June 2014).
18. Evans DG, Lalloo F, Cramer A et al: Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009; 46: 811-817.
19. Young SR, Pilarski RT, Donenberg T et al: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86.
20. Sharma P, Klemp JR, Kimler BF et al: Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/ or ovarian cancer syndrome testing 3. Breast Cancer Res Treat 2014; 145: 707-714.
21. Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R: Evaluation of models to predict BRCA germline mutations. Br J Cancer 2006; 95: 914-920.
22. Couch FJ, DeShano ML, Blackwood MA et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336: 1409-1415.
23. Frank TS, Deffenbaugh AM, Reid JE et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20: 1480-1490.
24. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancersusceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145-158.
25. Evans DG, Eccles DM, Rahman N et al: A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004; 41: 474-480.
26. Schmidt MK et al: BRCA1 and BRCA2 mutation spectrum in a hospital-based series of young breast cancer patients (unpublished).
27. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
28. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
29. Schmidt MK, Vermeulen E, Tollenaar RA, Vant Veer LJ, van Leeuwen FE: Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding. Eur J Cancer 2009; 45: 2376-2382.
30. Amir E, Freedman OC, Seruga B, Evans DG: Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010; 102: 680-691.
31. Honrado E, Benitez J, Palacios J: The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005; 18: 1305-1320.
32. STOET-VGKN. Dutch CGC referral criteria (Stichting Opsporing Erfelijke Tumoren -Vereniging Klinische Genetica Nederland (STOET-VGKN) criteria), edition 1996 and 2001.
33. Schlich-Bakker KJ, ten Kroode HF, Warlam-Rodenhuis CC, van den Bout J, Ausems MG: Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet Med 2007; 9: 766-777.
34. Van Riel E, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJ, Ausems MG: BRCA testing of breast cancer patients: medical specialists referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care (Engl) 2010; 19: 369-376.
35. Antoniou AC, Easton DF: Risk prediction models for familial breast cancer. Fut Oncol 2006; 2: 257-274.
36. Bouchardy C, Benhamou S, Fioretta G et al: Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 2011; 127: 233-241.
37. Warlam-Rodenhuis CC, Koot VC, van der Luijt RB, Vasen HF, Ausems MG: A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients. Eur J Cancer 2005; 41: 1409-1415.
38. Lakhani SR, Van De Vijver MJ, Jacquemier J et al: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
39. Kwon JS, Gutierrez-Barrera AM, Young D et al: Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010; 28: 4214-4220.
40. Robertson L, Hanson H, Seal S et al: BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 2012; 106: 1234-1238.
41. Weitzel JN, Lagos VI, Cullinane CA et al: Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007; 297: 2587-2595.
42. National Institute for Health and Care Excellence. CG164 Familial breast cancer: NICE guidance. Available at:. http://guidance.nice.org.uk/CG164/NICEGuidance/pdf/ English 2013 (last accessed on 26 June 2014).